宫颈癌中血管内皮生长因子、环氧合酶-2的表达及意义

目的　探讨环氧合酶 - 2 (COX - 2 )在宫颈癌中的表达 ,及其与血管内皮生长因子 (VEGF)表达和肿瘤微血管密度 (MVD)的关系。方法　应用免疫组化法检测 5 4例宫颈癌中COX - 2、VEGF的表达和MVD值 ,并以 1 0例宫颈CIN和 1 0例正常宫颈上皮为对照组。结果　宫颈癌中COX - 2阳性表达率分别为Ⅰ期5 6 7%、Ⅱ期为 6 6 7%、Ⅲ期 77 8%。VEGF在宫颈癌中阳性表达率分别为Ⅰ期 76 7%、Ⅱ期 80 0 % ,Ⅲ期88 9%。COX - 2在宫颈癌Ⅰ、Ⅱ、Ⅲ期间差异无显著性 (P >0 0 5 )。VEGF宫颈癌Ⅰ、Ⅱ期间差异无显著性 (P>0 0 5 ) ,Ⅰ期与Ⅲ期之间差异有显著性 (P <0 0 5 )。COX - 2、VEGF与MVD的表达呈正相关 ,而与不同的病理分级无明显相关性 (P >0 0 5 )。结论　VEGF、COX - 2、MVD在宫颈癌的发生、发展过程中起着重要作用 ,VEGF、COX - 2、MVD值可作为检测指标 ,为宫颈癌的诊断、临床分期及治疗起指导作用     

子宫内膜异位症与抗碳酸酐酶抗体的关系

目的 :探讨抗碳酸酐酶Ⅰ、Ⅱ抗体与子宫内膜异位症的关系。方法 :应用酶联免疫吸附 (ELISA)法分别检测内异症 32例、其他妇科疾病 (妇科组 ) 2 0例及正常妇女 12例血清抗碳酸酐酶抗体水平。结果 :(1)内异症患者血清抗碳酸酐酶Ⅰ、Ⅱ抗体阳性率(87.5 %、5 3.1% )高于妇科组 (2 5 %、15 % ) ,两组差异有显著性 (P <0 .0 1) ;(2 )内异症患者血清抗碳酸酐酶Ⅰ、Ⅱ抗体阳性率明显高于正常妇女组 (0 %、0 % ) ,两组差异有显著性 (P<0 .0 1) ;(3)妇科组及正常妇女组血清抗碳酸酐酶Ⅰ、Ⅱ抗体阳性率较低 ,两组差异无显著性 (P >0 .0 5 )。结论 :检测抗碳酸酐酶抗体对诊断子宫内膜异位症及探讨其发病机制有重要价值     

生殖健康与肿瘤普查

妇科肿瘤是妇科的常见疾病之一 ,其中宫颈癌、卵巢癌、子宫内膜癌三大恶性肿瘤严重威胁着妇女的健康与生命。随着社会的发展 ,一些肿瘤的流行病学因素也在不断的发生变化。如伴随人乳头瘤病毒 (ＨＰＶ)感染的蔓延和播散 ,宫颈癌的发病年龄已经出现明显的年轻化趋势 ,子宫内膜癌的发病率也在与日俱增 ,尽管对卵巢癌的病因、早期诊断及治疗方法国内外都作了大量的研究 ,但卵巢癌的 5年存活率始终没有得到明显提高。因此 ,对妇科恶性肿瘤的普查显得尤为重要。尽量做到早发现、早诊断、早治疗。1　重视子宫颈癌的普查　　我国对宫颈癌普查是开展…     

卵巢癌早期诊断的血清肿瘤标志物研究进展

卵巢癌死亡率居妇科恶性肿瘤之首.由于早期临床症状隐匿,缺乏有效的早期诊断方法,超过70%的患者就诊时已是临床晚期.早期卵巢癌患者5年生存率为70%～90%,而晚期卵巢癌患者的5年生存率仅为20%.因此,早期诊断对卵巢癌的预后有重要影响.近年研究者致力于寻找特异度、灵敏度高的血清肿瘤标志物,如CA125、卵巢癌差异蛋白4(HFA)、可溶性问皮素相关蛋白(SURF)、人激肽释放酶(Hk)、CA72-4和骨桥蛋白(OPN)等,以及血清标记物的联合检测,并取得一系列进展.对卵巢癌早期诊断的血清肿瘤标志物研究进展综述.     

老年妇女不规则阴道出血与妇科恶性肿瘤

国内外报道 ,老年妇女不规则阴道出血病因中 ,妇科恶性肿瘤所占比例近年来有逐渐下降趋势 ,围绝经期妇女不规则阴道出血病因中妇科恶性肿瘤约占 10 % ,绝经后出血中妇科恶性肿瘤约占 2 5 % [1] ,本文仅就老年妇女不规则阴道出血与妇科恶性肿瘤的关系做一简述。1　导致老年妇女不规则阴道出血常见的妇科恶性肿瘤导致老年妇女不规则阴道出血的妇科恶性肿瘤以子宫内膜癌为常见 ,宫颈癌及卵巢癌次之 ,阴道癌、输卵管癌较少见。1 1　子宫内膜癌　系老年妇女常见肿瘤 ,肥胖、晚绝经及高血压病等为危险因素 ,患者平均年龄在 5 5岁左右 ,5 0～6 0岁…     

宫颈癌组织中环氧合酶-2和诱生型一氧化氮合酶的表达及其意义

目的 :研究环氧合酶 2 (COX 2 )和诱生型一氧化氮合酶(iNOS)在宫颈癌发生发展中的作用。方法 :用免疫组化方法检测 80例宫颈癌患者COX 2和iNOS的表达水平 ,并以 3 1例宫颈上皮内瘤样病变(CIN)、3 0例慢性宫颈炎症患者和 3 0例正常宫颈上皮为对照组。结果 :(1 )宫颈癌患者COX 2和iNOS表达阳性率分别为 5 8.75 %和 86.2 5 % ,高于CIN、慢性宫颈炎症患者和正常宫颈上皮组 ;(2 )宫颈癌患者COX 2和iNOS的表达水平与临床分期、组织学分型及细胞分化程度无关 (P >0 .0 5 ) ;(3 )伴淋巴结转移的宫颈癌患者COX 2的表达水平略高于不伴淋巴结转移者 ,但差异无显著性 (P >0 .0 5 ) ,而iNOS的表达水平明显高于不伴淋巴结转移者 (P <0 .0 5 ) ;(4 )肿瘤直径≥ 5cm的宫颈癌患者COX 2的阳性表达率明显高于肿瘤直径 <5cm者 (P <0 .0 5 ) ,而iNOS的阳性表达率高于肿瘤直径 <5cm者 ,但差异无显著性 (P >0 .0 5 ) ;(5 )伴宫旁浸润或脉管浸润的宫颈癌患者COX 2和iNOS表达水平明显高于不伴宫旁浸润或脉管浸润者 (P <0 .0 1 ) ;(6)宫颈癌患者COX 2和iNOS的表达之间无相关性 ,而慢性宫颈炎症患者COX 2和iNOS的表达之间有相关性。结论 :宫颈癌患者COX 2和iNOS的表达水平明显上调 ,其表达与宫颈癌的发生发展有关     

老年妇科恶性肿瘤160例临床分析

目的 :探讨老年妇科恶性肿瘤的临床特点及防治经验 ,提出有效保健措施。方法 :回顾分析 16 0例老年妇科恶性肿瘤的病历资料。结果 :6 4例宫体癌居首位 ,其次是卵巢癌 6 2例 ,12例宫颈癌为第 3位。 16 0例中 88例 (5 5 % )以阴道出血为主诉就诊 ,90例(5 6 .2 5 % )有内外科合并症。术前合并内外科疾病的肿瘤患者发生术后并发症例数与无合并症者发生的例数之间差异有高度显著性 (P <0 .0 1)。结论 :子宫内膜癌发病率有上升趋势 ;阴道超声及宫腔细胞学联合检查是较好的筛查内膜癌及癌前病变的方法 ;对老年患者术前应积极治疗合并症 ,加强围手术期的处理 ,减少并发症的发生。只要处理得当、在严密监护下老年人几乎可以耐受各种妇科手术。加强妇女保健、开展普查普治是降低妇科恶性肿瘤发病率 ,提高治愈率的有效措施     

eIF-4E、OPN在上皮性卵巢癌患者血清中的表达及临床意义

目的:检测eIF-4E、OPN在上皮性卵巢癌患者血清中的表达,探讨eIF-4E、OPN作为肿瘤标志物,与CA125联合检测的临床意义。方法:采集卵巢上皮性癌46例,卵巢交界性上皮性肿瘤16例、卵巢良性上皮性肿瘤12例及健康妇女12例的血清标本,用双抗体夹心(ELISA)法检测血清标本中eIF-4E、OPN的浓度,血清CA125浓度用化学发光法检测。结果:卵巢恶性肿瘤组及交界性肿瘤组血清中eIF-4E、OPN、CA125的浓度明显高于卵巢良性肿瘤组及正常对照组。eIF-4E检测阳性率63.04%,OPN检测阳性率76.9%,CA125检测阳性率71.74%,eIF-4E和CA125联合检测阳性率93.48%,OPN和CA125联合检测阳性率89.13%,eIF-4E、OPN及CA125三者联合检测阳性率97.83%。Ⅲ、Ⅳ期卵巢癌患者血清中CA125、eIF-4E、OPN浓度明显高于Ⅰ、Ⅱ期。结论:eIF-4E、OPN可作为卵巢肿瘤标志物,用于卵巢癌早期诊断,与CA125联合检测有较高的临床应用价值。     

妇科肿瘤病人治疗后阴道镜的随访价值

1925年Hinselmann首先介绍用阴道镜诊断早期宫颈癌,近十年来在美国已普遍使用。作者自1974年11月1日到1979年7月1日对108例治疗后的妇科肿瘤病人共做350次阴道镜检查,最初的恶性肿瘤包括56例宫颈癌,27例子宫内膜癌,13例卵巢癌,4例外阴癌,2例阴道癌,2例卵管癌,4例子宫肉瘤,每例检查1-11次(平均3-4次),检查前均作巴氏涂片,用3%醋酸作指示(但非为常规),对可疑区作活检。     

Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium

OBJECTIVES: Cyclooxygenase-1 and 2 (COX-1 and COX-2) play important roles in normal physiology and are often dysregulated in neoplastic tissues. The present study determines whether COX-1 and COX-2 are expressed in ovarian cancers and whether the pattern of expression of these enzymes reveals clues to their roles in this cancer. METHODS: The expression of COX-1 and COX-2 proteins in 9 normal human ovaries, in 137 cases of ovarian cancers of epithelial origin (83 primary and 54 metastatic), and in 7 ovarian cancer cell lines was examined by immunohistochemistry and western analysis. RESULTS: COX-1 protein was present in 95/137 (69.3%) of the total cancers studied, with 55/83 (66.3%) of the primary cancers and 40/54 (74.1%) of the metastatic cancers positive for protein. COX-2 was present in 97/137 (70.8%) of all cancers studied, with 53/83 (63.9%) of the primary cancers and 44/54 (81.5%) of the metastatic cancers positive for protein. Notably, the quickscores for COX-2-positive staining were significantly higher in metastatic cancers. Moreover, COX-2 immunostaining was frequently found at the advancing margin of tumor invasion or in new metastatic loci. COX-1 protein expression was observed in the ovarian surface epithelial cells, especially that of the inclusion cysts. COX-1 was also detected by western blot in seven of nine ovarian cancer cell lines. However, no COX-2 was detected in either normal epithelium or cancer cell lines. CONCLUSION: COX-1 and COX-2 were expressed in every type of ovarian epithelial cancer, suggesting that each may contribute to the cancer development or progression.     

卵巢上皮性癌患者肿瘤组织和血清KLK8的表达及临床意义

目的:探讨激肽释放酶8(KLK8)在卵巢癌中的表达及其意义。方法:免疫组化法检测卵巢上皮性肿瘤组织中KLK8蛋白的表达水平,其中良性卵巢肿瘤20例、交界性卵巢肿瘤11例、卵巢癌62例,并测量其平均灰度值(A值);酶联免疫吸附(ELISA)双抗体夹心法检测血清KLK8浓度;分析卵巢癌组织中KLK8表达的A值与血清浓度值之间的相关性,比较血清KLK8、CA125检测用于卵巢癌诊断的敏感度及特异度。结果:(1)良性卵巢肿瘤、交界性卵巢肿瘤及卵巢癌中KLK8阳性表达率分别为25%(5/20)、27.3%(3/11)及66.1%(41/62),卵巢癌组阳性表达率明显高于前两组(P<0.05)。在不同临床病理特征间,差异亦有统计学意义(P<0.05);(2)血清KLK8浓度分别为4.26±0.29、5.26±0.46、6.59±0.15μg/L,差异有统计学意义(P<0.01);(3)卵巢癌组织KLK8表达的A值为156.4±14.7,与血清浓度值呈显著正相关,Spearman等级相关系数为0.608(P<0.001);(4)KLK8用于卵巢癌诊断的敏感度61.3%,特异度77.4%,与CA125差异无统计学意义(P>0.05)。结论:卵巢癌组织及血清中KLK8蛋白表达升高,并参与卵巢上皮性癌的发生发展过程,血清KLK8检测可指导卵巢癌的早期诊断。     

TP/TC方案新辅助化疗对原发性上皮性卵巢癌ER-CC1、BRCA1及β-tubulinⅢ表达的影响

目的:探讨原发性上皮性卵巢癌患者紫杉醇+铂类(TP/TC)方案的新辅助化疗对核苷酸切除修复交叉互补基因1(ERCC l)、乳腺癌易感基因1(BRCA l)及β-微管蛋白Ⅲ(β-tubulinⅢ)表达的影响及临床意义。方法:应用免疫组化技术检测48例原发性上皮性癌患者组织标本(其中以TP/TC方案行新辅助化疗15例)中ERCC l、BRCA l及β-tubulinⅢ蛋白表达。结果:ERCCl蛋白主要在卵巢癌细胞核表达,细胞浆有少量表达;BRCAl蛋白在细胞核表达;β-tubulinⅢ在细胞胞浆中表达。新辅助化疗组中ERCC1蛋白高表达率(66.67%)显著高于术前未行化疗组(30.30%),差异有统计学意义(P0.05);新辅助化疗组中BRCA1蛋白高表达率(20%)高于术前未行化疗组(3.03%),但差异无统计学意义(P0.05);新辅助化疗组中β-微管蛋白Ⅲ高表达率(60%)高于术前未行化疗组(57.58%),但差异无统计学意义(P0.05)。结论:含铂新辅助化疗可能通过诱导ERCC1的表达增加卵巢上皮癌对铂类的耐药性。TP/TC新辅助化疗可能上调BRCA1及β-tubulinⅢ蛋白在卵巢上皮癌中的表达。     

COX-1 and COX-2 expression in stage I and II invasive cervical carcinoma: relationship to disease relapse and long-term survival

COX-1 and COX-2 are members of the cyclooxygenase (COX) family, which influence tumor invasion and apoptosis. The objective of the study was to assess the relationship between COX-1 and COX-2 expression in early-stage disease and subsequent disease relapse and long-term survival. Women with FIGO stage I and II cervical carcinoma, younger than 50 years, treated between 1981 and 1990 were included. COX-1 and COX-2 expressions in the tumors were assessed by immunohistochemistry. COX-1 and COX-2 were expressed in 61% (17/28) and 57% (16/28) of tumors, respectively. COX-1 nonexpressers showed an improved overall survival compared to expressers (log-rank test, P= 0.09). There was no significant difference in the overall survival in COX-2 nonexpressers compared to expressers (P= 0.6). Out of eight women with disease relapse, COX-1 or COX-2 expression was noted in six of eight tumors, and both were expressed in five of eight tumors. Our preliminary data suggest an adverse prognosis with COX-1 expression in early-stage cervical carcinoma and a trend toward COX-1 expression in disease relapse. The association between COX-2 expression and a worse prognosis was not proven in this study.     

人抗原RmRNA与蛋白和环氧合酶-2蛋白在卵巢浆液性肿瘤组织中的表达及其意义

目的 探讨人抗原R（human antigen R,HuR）mRNA与蛋白和环氧合酶-2（COX-2）蛋白在卵巢浆液性肿瘤组织中的表达及其与卵巢浆液性癌临床病理生物学特征的关系。方法 采用RT-PCR技术、免疫组化方法分别检测中国医科大学附属盛京医院2006年1月至2008年2月收集的31例卵巢浆液性癌组织标本、22例卵巢浆液性良性瘤组织标本中HuR mRNA与蛋白和COX-2蛋白的表达,并以8例正常卵巢组织作为对照组。结果 （1）HuR mRNA在卵巢浆液性癌中表达明显高于卵巢浆液性良性瘤和正常卵巢组织（P<0.05）。HuR mRNA 的表达与卵巢浆液性癌细胞分化有关（P<0.05）,与手术病理分期、淋巴结转移无关（P>0.05）。（2）HuR蛋白相对含量和胞浆表达阳性率在卵巢浆液性癌中的表达显著高于卵巢浆液性良性瘤和正常卵巢组织（P<0.05）。HuR蛋白相对含量和胞浆表达阳性率与卵巢浆液性癌细胞分化有关（P<0.05）,与手术病理分期、淋巴结转移无关（P>0.05）。（3）COX-2蛋白相对含量与卵巢浆液性癌手术病理分期有关（P<0.05）,与细胞分化、淋巴结转移无关（P>0.05）。依据31例卵巢浆液性癌中免疫组化结果半定量分析,经Spearman等级相关分析发现HuR与COX-2之间呈正相关（r=0.680,P=0.000）。结论 卵巢浆液性肿瘤的发展与胞浆中HuR的过表达有一定相关性,HuR与COX-2蛋白在卵巢浆液性癌中的表达呈正相关。     

MIB-1: a predictor of survival in patients with ovarian carcinoma

Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. MIB-1: A predictor of survival in patients with ovarian carcinoma. Int J Gynecol Cancer 1998; 8 : 392–396.
Objective: MIB-1, a monoclonal antibody, reacts with the Ki-67 antigen, functioning as a marker of proliferation index. This study was carried out to determine whether MIB-1 staining, using image analysis, was a prognostic indicator in patients with ovarian carcinoma.
Methods: The tumors from 93 consecutive patients receiving primary surgical therapy for ovarian cancer were evaluated with MIB-1. Staining was quantified by image analysis. The patients were followed for a mean of 41 months (median, 37 months; minimum, 27 months; maximum, 68 months). Their charts were reviewed to determine survival, histologic type, grade, stage, and level of cytoreduction.
Results: Seventy-three patients had serous carcinomas, eight clear cell carcinomas, four endometrioid carcinomas, four mucinous carcinomas, two transitional carcinomas, and two undifferentiated carcinomas. Sixteen patients had stage I disease, four patients had stage II disease, 53 patients had stage III disease, and 20 patients had stage IV disease. Thirty-nine patients died within the observation period of the study. The MIB-1 staining of those patients alive at the conclusion of the study (28.3%) was significantly less than the MIB-1 staining of those who died (42.6%) ( P < 0.001). No patient whose tumor had MIB-1 staining of less than 22.0% died during the observation period of the study. MIB-1 staining less than 22.0% ( P = 0.020), FIGO stage ( P = 0.025), and the level of cytoreduction ( P = 0.0006) were independent predictors of survival.
Conclusion: In this series of 93 patients with ovarian carcinoma, MIB-1 monoclonal antibody staining was shown to be an independent prognostic indicator of survival. No patient whose tumor stained less than 22% positive nuclear area for MIB-1 died of her ovarian carcinoma.     

环氧合酶-2蛋白及前列腺素类物质与卵巢浆液性癌生物学行为的关系

目的　研究环氧合酶 2 (COX 2 )以及前列腺素类物质与卵巢浆液性肿瘤发生、发展的关系。方法　采用免疫印迹法及放射免疫法对 5 4例卵巢浆液性肿瘤组织 (其中良性卵巢浆液性肿瘤 11例 ,交界性良性卵巢浆液性肿瘤 10例 ,卵巢浆液性癌 3 3例 )和 10例正常卵巢组织进行COX 2蛋白、前列腺素 (PG)E2 、6 酮 前列腺素F1α(6 keto PGF1α)及血栓素 (TX)B2 水平检测。结果　 (1)COX 2蛋白表达 :卵巢浆液性癌组织的阳性表达率为 82 % (2 7/ 3 3 )、相对含量为 2 0 0 8± 3 5 3 ,交界性卵巢浆液性肿瘤分别为 90 % (9/ 10 )、2 0 61± 3 0 3 ,均明显高于良性卵巢浆液性肿瘤及正常卵巢 (阳性表达率均为0 ,相对含量分别为 15 0 4± 0 12及 15 3 3± 0 60 ) ,差异均有显著性 (P <0 0 5 ) ;卵巢浆液性癌患者不同临床分期 (Ⅰ～Ⅱ期与Ⅲ～Ⅳ期 )、病理分级及有无腹水、有无淋巴结转移间比较 ,差异均无显著性 (P>0 0 5 )。 (2 )前列腺素类物质PGE2 、6 keto PGF1α及TXB2 水平 :卵巢浆液性癌明显高于交界性、良性肿瘤和正常卵巢 (P <0 0 5 ) ,而后 3者间比较 ,差异无显著性 (P >0 0 5 ) ;卵巢浆液性癌患者不同临床分期 (Ⅰ～Ⅱ期与Ⅲ～Ⅳ期 )、病理分级及有无腹水、有无淋巴结转移间比较 ,差异均无显著性 (     

子宫内膜癌组织中环氧化酶-2增强表达的临床意义

目的:探讨环氧化酶2(COX2)在子宫内膜癌组织中的表达,COX2与雌激素受体(ER)表达的关系及COX2在子宫内膜癌发生发展中的意义。方法:应用RTPCR技术检测30例子宫内膜癌、相应癌旁正常内膜腺体及15例子宫良性肿瘤中COX2mRNA的表达。应用免疫组化方法测定30例内膜癌中ER表达情况。结果:COX2mRNA在30例子宫内膜癌组织中有28例表达水平明显增高,癌组织与正常内膜腺体或良性肿瘤间COX2的表达差异有显著性意义(P<0.05)。ER阳性组与ER阴性组的COX2表达差异有非常显著性意义(P<0.01)。结论:子宫内膜癌组织中COX2mRNA表达水平高于正常内膜腺体或子宫良性肿瘤,激素依赖型子宫内膜癌中COX2表达高于非激素依赖型内膜癌且其表达在子宫内膜癌的发生、发展中具有重要意义。     

Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1

Metastasis-suppressor genes, by definition, suppress metastasis without affecting tumorigenicity and, hence, present attractive targets as prognostic or therapeutic markers. BRMS1 (breast cancer metastasis suppressor) has recently been identified as a metastasis-suppressor gene for human breast cancer and melanoma. Expression of BRMS1 messenger RNA (mRNA) in multitissue including normal prostate, ovarian, testis, and colon has been detected by northern blot analysis. We hypothesize that the role of BRMS1 in tumor progression may not be limited to breast cancer and melanoma. We previously found that BRMS1 mRNA levels in primary ovarian epithelial carcinomas were significantly lower than that in normal ovarian and benign tumors (P < 0.05), and statistical analysis of BRMS1 mRNA levels revealed that BRMS1 mRNA levels were significantly higher in early tumor stages (I, II) compared with advanced tumor stages (III, IV) in which lymph node or distant metastases were present (P < 0.01). Our data showed that reduced BRMS1 mRNA seems to influence ovarian carcinoma metastatic ability. Therefore, we transfected BRMS1 plasmid into highly malignant ovarian carcinoma cell line, HO-8910PM, and examined cell biologic behaviors including proliferation, adhesion, invasion, and metastasis in vitro and in vivo. BRMS1 expression did not alter the proliferation of HO-8910PM cells in vitro and primary tumor formation in vivo. But, BRMS1 expression significantly suppressed the cell adhesion to extracellular matrix components and in vitro cell invasion in BRMS1-transfected HO-8910PM cells compared to parental HO-8910PM and vector-only transfectants (HO-8910PM-vect). Furthermore, motility of BRMS1 transfectants was inhibited. lung colony formation of intravenously injected BRMS1 transfectants in nude mice was significantly reduced. Also, BRMS1 transfectants form significantly less metastatic to organs of peritoneal cavity in orthotopically implanted ovarian tumor nude models. We further discovered that BRMS1 expression did downregulate expression of an actin-bundling protein associated with cell motility -fascin, which perhaps is the mechanism underlying BRMS1 suppression of metastasis. These data suggested that in addition to its already described role in breast cancer and melanoma, BRMS1 functions as a metastasis-suppressor gene in ovarian carcinoma by modifying several metastatic-associated phenotypes, offering a new target for therapeutic intervention.     

肿瘤相关粘蛋白MUC1及其同种型MUC1/Y与卵巢上皮性肿瘤关系的研究

目的探讨肿瘤相关粘蛋白MUC1及其同种型 MUC1/Y粘蛋白在卵巢上皮性肿瘤的变化特征.方法采用免疫组化ABC法,对72例卵巢上皮性、浆液性和粘液性肿瘤组织和8例正常卵巢组织 MUC1和MUC1/Y粘蛋白进行检测.结果 MUC1在卵巢癌中的表达率(80%)高于良性上皮性肿瘤(45%)和正常卵巢组织(37.5%), P<0.005.MUC1/Y仅在卵巢癌中表达,二者高表达,与卵巢癌的恶性程度高、组织分化差、癌瘤播散及淋巴结转移有关.结论 MUC1、MUC1/Y作为一种新型的肿瘤标志物,与卵巢癌的发生、发展密切相关.